Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: June 30, 2022 Report Code: GDGMDHC22227IDB-ST

Select Item

Peritoneal cancer develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus, and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea, and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy, and radiation therapy.

The Peritoneal cancer pipeline drugs market research report provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peritoneal cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal cancer (Oncology) and features dormant and discontinued projects.

Peritoneal Cancer Pipeline Drugs Market Analysis by Key Targets

Some of the key targets in the Peritoneal cancer pipeline drugs market are Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD, Tubulin, Programmed Cell Death Protein 1, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD, and Programmed Cell Death 1 Ligand 1.

Peritoneal Cancer Pipeline Drugs Market, by Targets

Peritoneal Cancer Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanism of Actions in the Peritoneal Cancer Pipeline Drugs Market

Some of the key mechanisms of action in the Peritoneal cancer pipeline drugs market are Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Tubulin Inhibitor, Programmed Cell Death Protein 1 Antagonist, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, and Programmed Cell Death 1 Ligand 1 Inhibitor.

Peritoneal Cancer Pipeline Drugs Market, by Mechanism of Actions

For more mechanism of action insights, download a free report sample

Key Routes of Administration in the Peritoneal Cancer Pipeline Drugs Market

The key routes of administration in the Peritoneal cancer pipeline drugs market are intravenous, oral, subcutaneous, intraperitoneal, parenteral, intravenous drip, intratumor, and intradermal.

Peritoneal Cancer Pipeline Drugs Market, by Routes of Administration

Peritoneal Cancer Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Peritoneal Cancer Pipeline Drugs Market

The key molecule types in the Peritoneal cancer pipeline drugs market are small molecule, monoclonal antibody, monoclonal antibody conjugated, cell therapy, gene-modified cell therapy, and fusion protein.

Peritoneal Cancer Pipeline Drugs Market, by Molecule Types

Peritoneal Cancer Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Peritoneal Cancer Pipeline Drugs Market

Some of the key companies in the Peritoneal cancer pipeline drugs market are AstraZeneca Plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, GSK plc, and Pharma Mar SA.

Peritoneal Cancer Pipeline Drugs Market, by Companies

Peritoneal Cancer Pipeline Drugs Market, by CompaniesTo know more about the companies, download a free report sample

Market Report Overview

Key Targets Vascular Endothelial Growth Factor A, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD, Tubulin, Programmed Cell Death Protein 1, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD, and Programmed Cell Death 1 Ligand 1
Key Mechanism of Actions Vascular Endothelial Growth Factor A Inhibitor, Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NADInhibitor, Tubulin Inhibitor, Programmed Cell Death Protein 1 Antagonist, Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NADInhibitor, and Programmed Cell Death 1 Ligand 1 Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Intraperitoneal, Parenteral, Intravenous Drip, Intratumor, and Intradermal
Key Molecule Types Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Gene-Modified Cell Therapy, and Fusion Protein
Key Companies AstraZeneca Plc, Pfizer Inc, Advenchen Laboratories LLC, CSPC Pharmaceutical Group Ltd, GSK plc, and Pharma Mar SA

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Peritoneal cancer (Oncology).
  • Reviews of pipeline therapeutics for Peritoneal cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Peritoneal cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Peritoneal cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Peritoneal cancer (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Peritoneal cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Peritoneal cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

AB Science SA
AbbVie Inc
Acrivon Therapeutics Inc
ADC Therapeutics SA
Advenchen Laboratories LLC
AIM ImmunoTech Inc
AiVita Biomedical Inc
Akeso Inc
Aldeyra Therapeutics Inc
Alkermes Plc
ALX Oncology Holdings Inc
Amgen Inc
Anixa Biosciences Inc
Apexigen Inc
APIM Therapeutics AS
Apollomics Inc
Aprea Therapeutics Inc
Aravive Inc
Arch Oncology Inc
Artios Pharma Ltd
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioAtla Inc
BioIntegrator
BioInvent International AB
BioNTech SE
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Celldex Therapeutics Inc
Celsion Corp
CerRx Inc
Clover Biopharmaceuticals Ltd
Clovis Oncology Inc
Coherent Biopharma
Compugen Ltd
Context Therapeutics Inc
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Cristal Therapeutics BV
CSPC Pharmaceutical Group Ltd
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
Elucida Oncology Inc
ENB Therapeutics LLC
Enlivex Therapeutics Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
FUJIFILM Toyama Chemical Co Ltd
Genelux Corp
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
Gradalis Inc
Greenfire Bio LLC
GSK plc
Harpoon Therapeutics Inc
Hutchison MediPharma Ltd
I-Mab
ImmunityBio Inc
Immunocore Limited
ImmunoGen Inc
Immunotech Biopharm Ltd
Immutep Ltd
IMPACT Therapeutics Inc
Imugene Ltd
IMV Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Innovent Biologics Inc
Inspirna Inc
Instil Bio Inc
InxMed (Beijing) Co Ltd
Ionic Pharmaceuticals LLC
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Jina Pharmaceuticals Inc
Johnson & Johnson
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Kupffer Biotherapeutics Inc
Kyowa Kirin Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Leap Therapeutics Inc
Lee's Pharmaceutical Holdings Ltd
Lipac Oncology LLC
Lokon Pharma AB
MabVax Therapeutics Holdings Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Morvus Technology Ltd
MUCPharm Pty Ltd
Mycenax Biotech Inc
Northlake International LLC
Northwest Biotherapeutics Inc
Novartis AG
NuCana Plc
Nurix Therapeutics Inc
Nuvation Bio Inc
OBI Pharma Inc
Oncoinvent AS
OncoQuest Inc
Oncovir Inc
OncXerna Therapeutics Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Orano Med LLC
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
Pharmicell Co Ltd
Pharos iBio Co Ltd
Pionyr Immunotherapeutics Inc
Plexxikon Inc
Precigen Inc
Prestige BioPharma Ltd
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
R-Pharm US LLC
Recordati SpA
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Rhizen Pharmaceuticals SA
Rigel Pharmaceuticals Inc
Samyang Biopharmaceuticals Corp
Sanofi
Scancell Holdings Plc
Seagen Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sierra Oncology Inc
Soricimed Biopharma Inc
Sorrento Therapeutics Inc
STADA Pharmaceuticals (Asia) Ltd
Sumitomo Pharma Co Ltd
Sutro Biopharma Inc
Synermore Biologics Co Ltd
SynOx Therapeutics Ltd
Targovax ASA
TILT Biotherapeutics Ltd
Toray Industries Inc
Transgene SA
Ultimovacs AS
Vascular Biogenics Ltd
Verastem Inc
Viatris Inc
Vigeo Therapeutics Inc
Vivesto AB
Vyriad Inc
Xynomic Pharmaceuticals Holdings Inc
Y-mAbs Therapeutics Inc
Zenith Epigenetics Ltd
Zentalis Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peritoneal Cancer – Overview

Peritoneal Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peritoneal Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peritoneal Cancer – Companies Involved in Therapeutics Development

Peritoneal Cancer – Drug Profiles

Peritoneal Cancer – Dormant Projects

Peritoneal Cancer – Discontinued Products

Peritoneal Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more